tiletamine hydrochloride has been researched along with Stomach Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| He, X; Li, W; Li, X; Ma, J; Niu, N; Tao, H; Xia, Y; Xu, J; Xu, X | 1 |
| Alibeiki, F; Jafari, N; Karimi, M; Peeri Dogaheh, H | 1 |
| Haga, S; Kamiyama, T; Kataoka, A; Kina, M; Mino, K; Nakanishi, K; Ochiya, T; Ozaki, M; Sato, M; Takahashi, M; Takahashi, N; Todo, S; Umezawa, K; Yanagihara, K | 1 |
3 other study(ies) available for tiletamine hydrochloride and Stomach Neoplasms
| Article | Year |
|---|---|
Upregulation of miRNA‑301a‑3p promotes tumor progression in gastric cancer by suppressing NKRF and activating NF‑κB signaling.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclohexanones; Female; Gastrectomy; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; NF-kappa B; Prognosis; Repressor Proteins; Signal Transduction; Stomach; Stomach Neoplasms; Up-Regulation | 2020 |
Potent anti-cancer effects of less polar Curcumin analogues on gastric adenocarcinoma and esophageal squamous cell carcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclohexanones; Esophageal Squamous Cell Carcinoma; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Stomach Neoplasms | 2017 |
Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Line, Tumor; Cell Separation; Cyclohexanones; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |